Case reports of sustained HIV-1 remission, new drug approvals, and resistance testing provide patients with potential novel therapy approaches.
HIV Treatments and Guidelines Offer More Options Read More »
2018 was a record setting year for new drug approvals by the FDA. This article highlights some of the drugs that have new mechanisms of action or have indications that have not previously been available.
Overview of Selected Novel Drugs Approved in 2018 Read More »
HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.
This study aimed to assess the safety, tolerability, and pharmacokinetics of long-acting cabotegravir injections in healthy men not at high risk of HIV-1 infection.
Ibalizumab-uiyk (Trogarzo) is a new CD4-directed postattachment HIV-1 inhibitor approved for use in adults with multidrug resistant HIV-1 who have previously received multiple HIV medications and in whom current therapy is now failing.
New HIV Drug Treats Patients Unresponsive to Other Therapies Read More »
Ibalizumab has demonstrated both safety and efficacy in the treatment of HIV-1 infection. Its primary use will be in the setting of multidrug resistant virus as part of combination antiretroviral therapy. Further enhancements of ibalizumab to prolong its clearance and broaden its activity are in development.
Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor, indicated for use with other antiretroviral inhibitors in adults with multidrug resistant HIV-1 infection who aren’t responding to their antiretroviral regimen. It is considered an advance. But FDA approval was based on a study of only 40 people-and it had no control group.
Multidrug Resistant HIV Drug Lauded, But Clinical Foundation Not Very Deep. Read More »
TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development
Ibalizumab: First Global Approval Read More »
Ibalizumab-uiyk, marketed as Trogarzo, is the first HIV medication with a new mechanism of action to be approved in 10 years. The drug is a CD4–directed postattachment HIV-1 inhibitor intended for use along with other AR drugs in adults with no other treatment options. It prevents infection by binding to an immunoglobulin domain on CD4
New Option for Drug-resistant HIV Read More »
During a March 6 conference call for investors, Theratechnologies touted ibalizumab-uiyk as the first antiretroviral in its class, the first FDA-approved HIV-1 specific biological product, and the first HIV treatment that does not require daily administration. Officials said that the company was finalizing its pharmacy distribution network and expected the product to be available within
FDA approves novel biologic for resistant HIV infection Read More »
